How Bright A Light Do We Shine This Memorial Day?

By MIKE MAGEE  According to Veterans Administration historians, the origin of Memorial Day dates back to 1864 when three women from Boalsburg, Pennsylvania joined in grief to decorate the graves of family members who had died in the Civil War. A year later, other townspeople joined in and one year later, in 1866, women in…

Read More

KFF Health News’ ‘What the Health?’: Trump’s ‘One Big Beautiful Bill’ Lands in Senate. Our 400th Episode!

The Host Julie Rovner KFF Health News @jrovner @julierovner.bsky.social Read Julie’s stories. Julie Rovner is chief Washington correspondent and host of KFF Health News’ weekly health policy news podcast, “What the Health?” A noted expert on health policy issues, Julie is the author of the critically praised reference book “Health Care Politics and Policy A…

Read More

Inside the FDA’s Vaccine Uproar

Six days after a senior FDA official sent a sweeping internal email claiming that covid vaccines had caused the deaths of “at least 10 children,” 12 former FDA commissioners released an extraordinary warning in the Dec. 3 issue of the New England Journal of Medicine. They wrote that the claims and policy changes in the…

Read More

Implications of Congress Eliminating Major Biden Era Regulations for Medicaid

The Biden administration finalized several major Medicaid regulations with the intent of improving access to Medicaid services. Collectively, the rules span hundreds of pages of text, are extremely complex, and were set to be implemented over several years, with measurable increases in federal Medicaid spending. Overturning the rules would reduce regulation of managed care companies,…

Read More

Merck KGaA’s Rare Tumor Strategy Takes Shape With $3.9B SpringWorks Acquisition

SpringWorks Therapeutics brings to Merck KGaA two FDA-approved drugs, both currently under regulatory review in Europe. Beyond their initial applications in rare tumors, these small molecules are also being studied as monotherapies and as part of combinations treatments for certain cancers. The post Merck KGaA’s Rare Tumor Strategy Takes Shape With $3.9B SpringWorks Acquisition appeared…

Read More